纳武利尤单抗联合安罗替尼对Ⅲb~Ⅳ期NSCLC的疗效观察及对miR-1269、miR-204-5p表达的影响  

Observation of the Efficacy of Nabulizumab Combined with Anilotinib in AtageⅢb~ⅣNSCLC and the Effect on the Expression of miR-1269 and miR-204-5p

作　　者：张小裔[1] 屈肖杰 牛莎[1] ZHANG Xiaoyi;QU Xiaojie;NIU Sha(The Second People's Hospital of Jiaozuo,Jiaozuo,454000)

机构地区：[1]河南省焦作市第二人民医院,454000

出　　处：《实用癌症杂志》2024年第9期1516-1519,1528,共5页The Practical Journal of Cancer

摘　　要：目的探究纳武利尤单抗联合安罗替尼治疗Ⅲb~Ⅳ期非小细胞肺癌(NSCLC)患者的效果及对微小RNA-1269(miR-1269)、miR-204-5p表达的影响。方法选取Ⅲb~Ⅳ期NSCLC患者82例,患者分配为对照组、观察组,各41例,使用随机数字表法,对照组采用安罗替尼治疗,观察组在对照组的基础上采用纳武利尤单抗治疗;比较两组患者的疗效、治疗前后肿瘤标志物癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、miR-1269、miR-204-5p表达水平和不良反应的发生率。结果观察组患者治疗后疾病控制率(87.80%,36/41)显著高于对照组(68.29%,28/41)(χ^(2)=4.556,P=0.033);与治疗前相比,治疗后观察组和对照组的CEA、CYFRA21-1、miR-1269水平显著降低,miR-204-5p水平显著升高(P<0.05);治疗后与对照组相比,观察组的CEA、CYFRA21-1、miR-1269水平显著降低,miR-204-5p水平显著升高(P<0.05);不良反应两组间比较,差异无统计学意义(P>0.05)。结论纳武利尤单抗联合安罗替尼治疗Ⅲb~Ⅳ期NSCLC患者可降低患者肿瘤标志物的水平,调节miR-1269、miR-204-5p的表达,效果更好。Objective To investigate the effect of nivolumab combined with anlotinib on the expression of microRNA-1269(miR-1269)and miR-204-5p in patients with stageⅢb~Ⅳnon-small cell lung cancer(NSCLC).Methods 82 patients with stageⅢb toⅣNSCLC were selected,and the patients were allocated into the control group and the observation group,41 cases in each,using the random number table method,the control group was treated with anilotinib,and the observation group was treated with navulizumab on the basis of the control group.The curative effect,the expression levels of tumor markers carcinoembryonic antigen(CEA),cytokeratin 19 fragment 21-1(CYFRA21-1),miR-1269,miR-204-5p and the incidence of adverse reactions were compared between the 2 groups.Results The disease control rate of the observation group after treatment(87.80%,36/41)was obviously higher than that of the control group(68.29%,28/41)(χ^(2)=4.556,P=0.033);compared with before treatment,the levels of CEA,CYFRA21-1,and miR-1269 in the observation group and the control group were obviously reduced after treatment,while the level of miR-204-5p was obviously increased(P<0.05);after treatment,compared with the control group,the levels of CEA,CYFRA21-1,and miR-1269 in the observation group were obviously reduced,while the level of miR-204-5p was obviously increased(P<0.05);there was no statistically obvious difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion Nivolumab combined with anlotinib can reduce the level of tumor markers and regulate the expression of miR-1269 and miR-204-5p in patients with stageⅢb-ⅣNSCLC.

关 键 词：纳武利尤单抗 安罗替尼 Ⅲb~Ⅳ期 非小细胞肺癌 疗效 微小RNA-1269 微小RNA-204-5p 

分 类 号：R73-36[医药卫生—肿瘤]